Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Aerovate Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AEROVATE BOARD OF DIRECTORS APPROVES 1-FOR-35 REVERSE STOCK SPLIT WALTHAM, MASS. , APRIL 21, 2025 /PRNEWSWIRE/ -- AEROVATE THERAPEUTICS, INC. (NASDAQ: AVTE) ("AEROVATE") TODAY ANNOUNCED THAT ITS STOCKHOLDERS HAVE APPROVED THE PROPOSED MERGER (THE "MERGER") WITH JADE BIOSCIENCES, INC. ("JADE"), ALONG WITH ALL PROPOSALS RELATED TO THE MERGER.

AEROVATE THERAPEUTICS STOCKHOLDERS APPROVE PROPOSED MERGER WITH JADE BIOSCIENCES AND ALL RELATED PROPOSALS

AGGREGATE CASH DIVIDEND OF $69.6 MILLION, OR AN ESTIMATED $2.40 PER SHARE WALTHAM, MASS. , APRIL 9, 2025 /PRNEWSWIRE/ -- AEROVATE THERAPEUTICS, INC. (NASDAQ: AVTE) ("AEROVATE") TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DECLARED A SPECIAL CASH DIVIDEND (THE "CASH DIVIDEND") IN CONNECTION WITH THE PREVIOUSLY ANNOUNCED MERGER (THE "MERGER") WITH JADE BIOSCIENCES, INC. ("JADE") PURSUANT TO THE AGREEMENT AND PLAN OF MERGER, DATED OCTOBER 30, 2024 (THE "MERGER AGREEMENT").

AEROVATE THERAPEUTICS DECLARES SPECIAL CASH DIVIDEND IN CONNECTION WITH THE PROPOSED MERGER WITH JADE BIOSCIENCES

CASH DIVIDEND EXPECTED TO BE IN THE RANGE OF $67.6  69.6 MILLION WALTHAM, MASS. , APRIL 7, 2025 /PRNEWSWIRE/ -- AEROVATE THERAPEUTICS, INC. (NASDAQ: AVTE) ("AEROVATE") TODAY ANNOUNCED THAT, IN CONNECTION WITH ITS PREVIOUSLY ANNOUNCED MERGER (THE "MERGER") WITH JADE BIOSCIENCES, INC. ("JADE"), IT EXPECTS TO DECLARE A CASH DIVIDEND TO THE PRE-MERGER AEROVATE STOCKHOLDERS (THE "CASH DIVIDEND") IN THE RANGE OF $67.6  69.6 MILLION IN THE AGGREGATE.

AEROVATE THERAPEUTICS ANNOUNCES RANGE OF EXPECTED CASH DIVIDEND IN CONNECTION WITH THE PROPOSED MERGER WITH JADE BIOSCIENCES

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED MERGER OF AEROVATE THERAPEUTICS, INC. (NASDAQGM: AVTE) AND JADE BIOSCIENCES. PURSUANT TO THE TERMS OF THE AGREEMENT, SHAREHOLDERS OF AEROVATE WILL OWN APPROXIMATELY 1.6% OF THE COMBINED COMPANY. KSF IS SEEKING TO DETERMINE WHETHER THE MERGER AND THE PROCESS THAT LED TO IT ARE ADEQUATE, OR WHETHER THE M.

AEROVATE THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES MERGER OF AEROVATE THERAPEUTICS, INC. - AVTE

WALTHAM, MASS., JULY 08, 2024 (GLOBE NEWSWIRE) -- AEROVATE THERAPEUTICS, INC. (NASDAQ: AVTE), WHICH PREVIOUSLY ANNOUNCED IT WAS HALTING ENROLLMENT AND SHUTTING DOWN THE PHASE 3 PORTION OF THE INHALED IMATINIB PULMONARY ARTERIAL HYPERTENSION CLINICAL TRIAL (IMPAHCT) AS WELL AS THE LONG-TERM EXTENSION STUDY, TODAY ANNOUNCED THAT IT WILL CONDUCT A COMPREHENSIVE REVIEW OF STRATEGIC ALTERNATIVES FOCUSED ON MAXIMIZING SHAREHOLDER VALUE.

AEROVATE THERAPEUTICS TO EXPLORE STRATEGIC ALTERNATIVES

AV-101 DID NOT MEET THE PRIMARY ENDPOINT OF CHANGE IN PULMONARY VASCULAR RESISTANCE (PVR) FOR ANY OF THE STUDIED DOSES AV-101 DID NOT MEET THE PRIMARY ENDPOINT OF CHANGE IN PULMONARY VASCULAR RESISTANCE (PVR) FOR ANY OF THE STUDIED DOSES

AEROVATE THERAPEUTICS ANNOUNCES 24-WEEK TOPLINE RESULTS FROM THE PHASE 2B PORTION OF IMPAHCT EVALUATING AV-101 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

BASELINE CHARACTERISTICS REFLECT A PAH POPULATION WITH SIGNIFICANT DISEASE TOPLINE DATA FROM PHASE 2B PORTION OF IMPAHCT STUDY TO BE RELEASED IN JUNE 2024 ENROLLMENT INTO THE PHASE 3 PORTION OF IMPAHCT CONTINUES AT MORE THAN 120 SITES GLOBALLY WALTHAM, MASS., MAY 21, 2024 (GLOBE NEWSWIRE) -- AEROVATE THERAPEUTICS, INC. (NASDAQ: AVTE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DRUGS THAT MEANINGFULLY IMPROVE THE LIVES OF PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY PRESENTED A POSTER OUTLINING BASELINE CHARACTERISTICS FROM ALL PATIENTS ENROLLED IN THE DOSE-RANGING PHASE 2B PORTION OF THE INHALED IMATINIB PULMONARY ARTERIAL HYPERTENSION CLINICAL TRIAL (IMPAHCT) AT THE AMERICAN THORACIC SOCIETY (ATS) 2024 INTERNATIONAL CONFERENCE TAKING PLACE IN SAN DIEGO, CA.

AEROVATE THERAPEUTICS PRESENTS BASELINE DATA FROM THE PHASE 2B PORTION OF THE IMPAHCT TRIAL AT THE AMERICAN THORACIC SOCIETY 2024 INTERNATIONAL CONFERENCE

WALTHAM, MASS., MAY 13, 2024 (GLOBE NEWSWIRE) -- AEROVATE THERAPEUTICS, INC. (NASDAQ: AVTE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DRUGS THAT MEANINGFULLY IMPROVE THE LIVES OF PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2024, AND RECENT BUSINESS HIGHLIGHTS.

AEROVATE THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

WALTHAM, MASS., MARCH 27, 2024 (GLOBE NEWSWIRE) -- AEROVATE THERAPEUTICS, INC. (NASDAQ: AVTE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DRUGS THAT IMPROVE THE LIVES OF PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY ANNOUNCED AN UPCOMING POSTER PRESENTATION AT THE 2024 AMERICAN THORACIC SOCIETY (ATS) INTERNATIONAL CONFERENCE TAKING PLACE MAY 17-22, 2024, IN SAN DIEGO, CA. THE PRESENTATION WILL PROVIDE BASELINE CHARACTERISTICS FROM PATIENTS ENROLLED IN THE DOSE-RANGING PHASE 2B PORTION OF THE INHALED IMATINIB PULMONARY ARTERIAL HYPERTENSION CLINICAL TRIAL (IMPAHCT), A PHASE 2B/PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-NATIONAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF AV-101 IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION.

AEROVATE THERAPEUTICS TO PRESENT PATIENT BASELINE CHARACTERISTICS OF THE PHASE 2B PORTION OF THE PHASE 2B/PHASE 3 IMPAHCT TRIAL AT THE AMERICAN THORACIC SOCIETY 2024 INTERNATIONAL CONFERENCE

WALTHAM, MASS., MARCH 25, 2024 (GLOBE NEWSWIRE) -- AEROVATE THERAPEUTICS, INC.(NASDAQ: AVTE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DRUGS THAT MEANINGFULLY IMPROVE THE LIVES OF PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023, AND RECENT BUSINESS HIGHLIGHTS.

AEROVATE THERAPEUTICS ANNOUNCES FULL-YEAR 2023FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

WALTHAM, MASS., MARCH 06, 2024 (GLOBE NEWSWIRE) -- AEROVATE THERAPEUTICS, INC. (NASDAQ: AVTE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DRUGS THAT IMPROVE THE LIVES OF PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS ELECTED CURRENT BOARD MEMBER, HABIB DABLE, AS CHAIR OF THE BOARD. MR. DABLE SUCCEEDS MARK IWICKI, WHO WILL CONTINUE TO SERVE ON THE BOARD.

Aerovate Therapeutics, Inc.

AVTE

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

Aerovate Therapeutics, Inc.

AVTE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

AVTE